This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Anrukinzumab

Pfizer Inc.

Drug Names(s): IMA-638, PF-05230917

Description: Anrukinzumab is a humanized mouse monoclonal antibody to human IL-13. Preclinical studies suggest that IL-13 is a key mediator of asthma responses, including airway inflammation, obstruction and hyper-reactivity.

Deal Structure: Anrukinzumab was originally developed by Wyeth.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.


Anrukinzumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug